Australia markets open in 9 hours 42 minutes

Ikena Oncology, Inc. (IKNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.6750-0.0050 (-0.30%)
As of 10:17AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.6800
Open1.6700
Bid1.6500 x 100
Ask1.7000 x 200
Day's range1.6500 - 1.7000
52-week range1.0200 - 7.0000
Volume20,343
Avg. volume304,979
Market cap80.832M
Beta (5Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)-1.5700
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • Simply Wall St.

    It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year

    Key Insights Ikena Oncology's Annual General Meeting to take place on 7th of June CEO Mark Manfredi's total...

  • GlobeNewswire

    UPDATE – Ikena Oncology Announces Strategic Update

    Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development

  • GlobeNewswire

    Ikena Oncology Announces Strategic Update

    Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development